VTGN (Vistagen Therapeutics) Moat Score: 4/10 (As of Jun. 29, 2026)


VTGN Vistagen Therapeutics Inc VTGN
40 GF Score
Price $0.75
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Moat Score?

Vistagen Therapeutics VTGN +6.84% 40 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates VTGN with a GF Score™ of 40/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,401 Biotechnology companies, Vistagen Therapeutics ranks better than 88.79% on this metric.

Vistagen Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Vistagen Therapeutics has Narrow Moat: Vistagen Therapeutics Inc has a discernible but modest moat due to its focus on innovative therapies and some valuable intellectual property. However, it faces significant competition and lacks strong brand strength, market leadership, or regulatory barriers to establish a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vistagen Therapeutics might have Narrow Moat - Discernible but modest moat.

Vistagen Therapeutics  (NAS:VTGN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vistagen Therapeutics Moat Score Related Terms

VTGN vs PSTV, KYNB, TVGN: Moat Score Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Moat Score falls into.


VTGN
40GF Score
Vistagen Therapeutics Inc VTGN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Vistagen Therapeutics (VTGN) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vistagen Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Vistagen Therapeutics' Moat Score too high?
Vistagen Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Vistagen Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Moat Score compare to PSTV and KYNB?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #157 out of 1401 companies for Moat Score. This places Vistagen Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Vistagen Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.75 — trading 65.9% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.75 is trading 65.9% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Moat Score: 4
  • GF Value™: $2.20 vs. price of $0.75 (65.9% below fair value)
  • GF Score™: 40/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1401)

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for VTGN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price
$2.20
GF Value